Slide 1: Q1 2026 Earnings Call & Business Update
Q1 2026 Earnings Call & Business Update May 14, 2026 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Agenda
01 Executive Summary 02 Clinical and Regulatory 03 Virology and Pipeline agenda 04 Commercial 05 Financial 06 Q&A 3
Slide 4: Executive Summary
Executive Summary Rapid continued enrollment of DECLARATION pivotal study post- upsizing (+500 subjects) Expanded government affairs and corporate communications, including recent participation at POLITICO Health Care Summit and launch of ‘Antibodies for Any Body’ Campaign with Lindsey Vonn New prep
Slide 5: Invivyd: The Big Picture
Invivyd: The Big Picture PEMGARDA® ongoing growth in the face of declining vaccine utilization More rapid than expected demand Line of sight to changing for DECLARATION recruitment New analysis showing benefit of highly tolerable mAb vs vaccine COVID-19 prevention near- Broad consumer education on i
Slide 6: Government Affairs Update
Government Affairs Update Substantial increase in engagement with current administration and advisors Clear demonstrated interest in improvements to public health via novel vaccine-alternatives Plan to continue building awareness with long- term view toward scale and public health All trademarks and
Slide 7: Appreciating monoclonal antibodies appears universal
Appreciating monoclonal antibodies appears universal “[COVID mAb] wasn’t just a therapeutic. It just made me better. I “Give them the goddamn monoclonal antibodies when they get sick...” call that a cure.” - Joe Rogan, Podcaster, Nov. 2021 – President Donald Trump, Oct. 2020 “It was very disappointi
Slide 8: Lindsey Vonn Educating Americans on Antibody Immunology
Lindsey Vonn Educating Americans on Antibody Immunology All trademarks and logos displayed are the property of their respective owners. Their use here is for identification purposes only and does not constitute endorsement or affiliation. 8
Slide 9: Agenda
01 Executive Summary 02 Clinical and Regulatory 03 Virology and Pipeline agenda 04 Commercial 05 Financial 06 Q&A 9
Slide 10: VYD2311: REVOLUTION Program Updates
VYD2311: REVOLUTION Program Updates Pivotal Efficacy Study mAb & Vaccine Safety Pediatric Study and Immunology Study • Announced modest upsizing based on • Aligned with FDA on Phase 3 trial to • Agreed with FDA on Initial Pediatric conservative, pre-specified analysis examine safety and immunology o
Slide 11: New preprint explores immunization tolerability: COVID vaccines vs. IM mAb
New preprint explores immunization tolerability: COVID vaccines vs. IM mAb Patients Reporting ≥1 Systemic Reaction within 7 Days Post Immunization EVADE Study EVADE Study Invivyd conducted a post-hoc, exploratory analysis of (Unsolicited Events) 100% EVADE trial of adintrevimab to better understand
Slide 12: Symptom-Free Days
Our analysis demonstrates that vaccine systemic symptom burden can overwhelm the symptomatic benefit of disease prevention Arithmetic extrapolation of systemic reactogenicity symptom burden at the population level • Vaccines do not appear to have a positive net benefit on systemic symptomatic burden
Slide 13: Key Takeaways
Key Takeaways A very low VE (15-20%) monoclonal antibody could improve net systemic symptomatic benefit from immunization COVID vaccines generate meaningful symptom burden with uncertain benefit in the contemporary population Safety and tolerability of immunization is critical for broad uptake in he
Slide 14: Agenda
01 Executive Summary 02 Clinical and Regulatory 03 Virology and Pipeline agenda 04 Commercial 05 Financial 06 Q&A 14
Slide 15: Remarkable durability and stability of our COVID mAbs
We continue to see remarkable durability and stability of our COVID mAbs Circulating Proportions of US CDC Tracked Variants PEMGARDA® (pemivibart) and VYD2311 demonstrated positive in vitro neutralization against the emerging SARS- CoV-2 variant BA.3.2.2 (“Cicada”) mAb Activity Against CDC-Tracked V
Slide 16: Advancing broader pipeline of monoclonal antibodies against infectious disease
Continue to advance broader pipeline of monoclonal antibodies to combat infectious disease Measles RSV VMS063 VYD329 • Announced advancement of VMS063, a novel, potentially best-in- • Selected potential best-in- class mAb for the treatment and prevention of measles class RSV antibody candidate • Dem
Slide 17: Agenda
01 Executive Summary 02 Clinical and Regulatory 03 Virology and Pipeline agenda 04 Commercial 05 Financial 06 Q&A 17
Slide 18: PEMGARDA – Continued Growth
PEMGARDA – Continued Growth $13.7M PEMGARDA Q1 ’26 Established Strong Commercial Foundation 22% YoY Growth Net Product Revenue ~1,000 Accounts w/ PEMGARDA Infusion Experience Building from Specialty Infusion Team – Scaling to serve broad market for VYD2311, if approved ~1,850 Available Sites Infusin
Slide 19: Engaging HCPs via the AI they use most
Engaging HCPs via the AI they use most – Building an innovative footprint Early Results Encouraging PEMGARDA HCP queries increased in target clinicians AI powered platform and medical search engine used by healthcare providers for clinical decision support. 300% in Oncology 140% in Infectious Diseas
Slide 20: Increasing direct-to-consumer marketing to build consumer awareness
Increasing direct-to-consumer marketing to build consumer awareness Digital Display Ads Out of Home (OOH) Video Ads Social Media Ads “You Belong Here” “Will COVID be at the Party?” 8.5M 18K 63.8M 6.3M Impressions Site Visits Impressions Impressions (Meta + Reddit) Data from 1/1/26 through 3/31/26 20
Slide 21: Agenda
01 Executive Summary 02 Clinical and Regulatory 03 Virology and Pipeline agenda 04 Commercial 05 Financial 06 Q&A 21
Slide 22: Financial Update
Financial Update Q1 2026 PEMGARDA® net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Operating expense increase quarter-over-quarter primarily attributable to DECLARATION pivotal program costs for VYD2311 for which topline data is antic
Slide 23: OPEX increase driven by pivotal clinical spend, educational campaigns, and commercial infrastructure
Critical non-recurring investments in our near- term future OPEX Increase Q4’25 to Q1’26 (in millions) OPEX increase driven by pivotal clinical spend, educational campaigns, and commercial infrastructure Educational Pivotal Clinical Campaigns & Personnel & Q4’25 OPEX* Q1’26 OPEX* Spend Commercial Ot
Slide 24: Invivyd Inc.
INVIVYD INC. 24
Slide 25: Invivyd Inc.
INVIVYD INC.